Explore FABHALTA^® (iptacopan)

FOR PATIENTS WITH IgAN

The alternative complement pathway is thought to contribute to the pathogenesis of IgAN^1-4

Image showing the alternative pathway activation in IgAN

FOR ADULTS WITH PRIMARY IgAN AT RISK OF RAPID DISEASE PROGRESSION (UPCR ≥1.5 g/g)¹

FABHALTA is the first and only treatment to target the alternative complement pathway¹

Click on image to enlarge.

Interested in learning more?

Join an expert-led virtual discussion about FABHALTA for the reduction of proteinuria in adults with primary IgAN at risk of rapid disease progression (UPCR ≥1.5 g/g).

See trial results for FABHALTA

View efficacy

Start your patients on FABHALTA

See how

Definitions and References

Definitions
C3, complement 3; C5, complement 5; IgAN, immunoglobulin A nephropathy; UPCR urine protein-to-creatinine ratio.

References
1. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp.
2. Lim RS, Yeo SC, Barratt J, Rizk DV. An update on current therapeutic options in IgA nephropathy. J Clin Med. 2024;13(4):947. doi:10.3390/jcm13040947
3. Medjeral-Thomas NR, Troldborg A, Constantinou N, et al. Progressive IgA nephropathy is associated with low circulating mannan-binding lectin–associated serine protease-3 (MASP-3) and increased glomerular factor H–related protein-5 (FHR5) deposition. Kidney Int Rep. 2018;3(2):426-438. doi:10.1016/j.ekir.2017.11.015
4. Lai KN, Tang SC, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001. doi:10.1038/nrdp.2016.1

Explore FABHALTA® (iptacopan)

The alternative complement pathway is thought to contribute to the pathogenesis of IgAN1-4

FABHALTA is the first and only treatment to target the alternative complement pathway1